MIT-AD – The Czech-Norwegian joint project focused on discovering specific mitophagy biomarkers across Alzheimer’s Disease continuum

Welcome to the Czech-Norwegian joint project focused on discovering specific mitophagy biomarkers.

The Mit-AD project aims to develop early diagnostic biomarkers of Alzheimer’s disease (AD) by validating a series of new biomarkers in serum and cerebrospinal fluid (CSF) in participants from the Czech Brain Aging Study (CBAS). This Czech–Norwegian joint project will involve researchers from CBAS – Czech team with a unique clinical cohort and a top Norwegian research team specialized in mitophagy research.

konference Od mitofágie k neurokognitivním poruchám, pořádaná Neurologickou klinikou 2. LF UK a FN Motol s univerzitou v Oslu - Praha, Karolinum 11.4.2024
konference Od mitofágie k neurokognitivním poruchám, pořádaná Neurologickou klinikou 2. LF UK a FN Motol s univerzitou v Oslu - Praha, Karolinum 11.4.2024
konference Od mitofágie k neurokognitivním poruchám, pořádaná Neurologickou klinikou 2. LF UK a FN Motol s univerzitou v Oslu - Praha, Karolinum 11.4.2024

The Validation of specific mitophagy biomarkers across Alzheimer’s disease continuum benefits from a € 1 404 000 grant from Iceland, Liechtenstein and Norway through the EEA Grants and the Technology Agency of the Czech Republic within the KAPPA Programme.